ストックスクリーナーアプリを入手
24.60
0.36%
-0.09
Celldex Therapeutics Inc (CLDX) 最新ニュース
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Whats Radiant Logistics Incs historical returnQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Update Recap: Does Celldex Therapeutics Inc stock benefit from AI growthMarket Rally & AI Powered Market Entry Strategies - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance - Yahoo Finance
Will Celldex Therapeutics Inc. benefit from government policyJuly 2025 Summary & Stepwise Trade Signal Guides - mfd.ru
Celldex Therapeutics (CLDX) Investor Outlook: Analysts See Over 100% Upside Potential - DirectorsTalk Interviews
Growth Report: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Pullback Review & Consistent Income Trade Recommendations - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness - Sahm
Will Celldex Therapeutics Inc. stock hit new highs in YEARWeekly Stock Recap & Pattern Based Trade Signal System - mfd.ru
Day Trade: cờ tướng họcEarnings Growth Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest - MarketBeat
Pullback Watch: Whats the fair value of Celldex Therapeutics Inc stockWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates - Sahm
Value Recap: Is Celldex Therapeutics Inc stock resilient to inflationFed Meeting & Smart Allocation Stock Tips - Bộ Nội Vụ
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Unpacking a 107.86% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Celldex Therapeutics SVPs Engage In Heavy Transactions - AOL.com
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5%Here's Why - MarketBeat
Market Pulse: Can Celldex Therapeutics Inc disrupt its industryMarket Rally & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Can Celldex Therapeutics Inc disrupt its industry2025 Geopolitical Influence & Reliable Price Action Trade Plans - baoquankhu1.vn
How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story - Sahm
Will Celldex Therapeutics Inc. stock see insider buyingPortfolio Risk Summary & Detailed Earnings Play Strategies - ulpravda.ru
Will Celldex Therapeutics Inc. stock deliver better than expected guidanceQuarterly Profit Report & Advanced Swing Trade Entry Plans - Улправда
Why Celldex Therapeutics Inc. (TCE2) stock could be top winnerJuly 2025 Chart Watch & Fast Entry High Yield Tips - Улправда
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings - Sahm
Will Celldex Therapeutics Inc. stock attract more institutional investors2025 Market Overview & Precise Swing Trade Alerts - Улправда
Can Celldex Therapeutics Inc. stock deliver surprise earnings beatStop Loss & Daily Growth Stock Investment Tips - Улправда
How Celldex Therapeutics Inc. stock trades during market volatility2025 Analyst Calls & Fast Entry Momentum Trade Alerts - Улправда
Is Celldex Therapeutics Inc. stock a good choice for value investorsMarket Sentiment Summary & Smart Allocation Stock Reports - Улправда
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company - Barchart.com
Celldex Therapeutics Builds Momentum Around Barzolvolimab And Bispecific Antibody Programs - RTTNews
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics (CLDX) Stock Analysis: Biotechnology Innovator with Over 100% Upside Potential - DirectorsTalk Interviews
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% HigherShould You Buy? - MarketBeat
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9% - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Strong Buy Ratings and Nearly 96% Upside Potential - DirectorsTalk Interviews
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 - Insider Monkey
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely - Yahoo Finance
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX - MarketBeat
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick - Sahm
Income Plays: How sustainable is Celldex Therapeutics Inc. stock dividend payoutGDP Growth & AI Powered Trade Plan Recommendations - Улправда
Will Celldex Therapeutics Inc. stock outperform value stocksJuly 2025 Levels & Weekly High Potential Stock Alerts - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform growth indexesJuly 2025 Spike Watch & Verified Swing Trading Watchlists - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform tech sector in 2025Weekly Trade Summary & Low Volatility Stock Suggestions - Улправда
How Celldex Therapeutics Inc. stock performs after earningsInflation Watch & Stepwise Entry and Exit Trade Signals - Улправда
Aug Summary: Will Celldex Therapeutics Inc. stock see insider buying2025 Momentum Check & Real-Time Buy Signal Alerts - Улправда
Barclays Maintains Celldex Therapeutics (CLDX) Underweight Recommendation - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays - MarketBeat
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Bellevue Group AG Has $67.31 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Eventide Asset Management LLC Lowers Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
1.27%
大文字化:
|
ボリューム (24 時間):